Haleon, a world-leading consumer health company, completed the repurchase of $400 million in ordinary shares from Pfizer. Concurrently with this direct share buyback, Pfizer completed a $3.1 billion U.S. registered secondary global offering of more than 790 million ordinary shares and American depositary shares. The two transactions reduced Pfizer’s ownership in Haleon from 32 percent to 22.6 percent.
The S&C team advising Haleon included Frank Aquila, John Horsfield-Bradbury, Abi Yevnin, Jim Simpson, Paul Rota, Giada Ginevra Tagliabue, Becki Thompson and Amir Perk. Eric Wang, John Jo and James Patton advised on U.S. tax matters. Tracey Russell advised on FINRA matters.